Bacteria as Nanoparticle Carriers for Immunotherapy in Oncology
Open Access
- 3 April 2022
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (4) , 784
Abstract
The use of nanocarriers to deliver antitumor agents to solid tumors must overcome biological barriers in order to provide effective clinical responses. Once within the tumor, a nanocarrier should navigate into a dense extracellular matrix, overcoming intratumoral pressure to push it out of the diseased tissue. In recent years, a paradigm change has been proposed, shifting the target of nanomedicine from the tumoral cells to the immune system, in order to exploit the natural ability of this system to capture and interact with nanometric moieties. Thus, nanocarriers have been engineered to interact with immune cells, with the aim of triggering specific antitumor responses. The use of bacteria as nanoparticle carriers has been proposed as a valuable strategy to improve both the accumulation of nanomedicines in solid tumors and their penetration into the malignancy. These microorganisms are capable of propelling themselves into biological environments and navigating through the tumor, guided by the presence of specific molecules secreted by the diseased tissue. These capacities, in addition to the natural immunogenic nature of bacteria, can be exploited to design more effective immunotherapies that yield potent synergistic effects to induce efficient and selective immune responses that lead to the complete eradication of the tumor.Keywords
Funding Information
- ministerio de ciencia e innovacion (spain) (PID2019-106381RB-I00)
This publication has 133 references indexed in Scilit:
- Inducers of immunogenic cancer cell deathCytokine & Growth Factor Reviews, 2013
- Systemic cancer therapy: achievements and challenges that lie aheadFrontiers in Pharmacology, 2013
- Delivering nanomedicine to solid tumorsNature Reviews Clinical Oncology, 2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Tolerance, immune regulation, and autoimmunity: cells and cytokines that make a differenceCurrent Opinion in Immunology, 2008
- Bacteria-mediated delivery of nanoparticles and cargo into cellsNature Nanotechnology, 2007
- Cancer immunoediting from immune surveillance to immune escapeImmunology, 2007
- Biologic therapies: what and when?Journal of Clinical Pathology, 2007
- Chemotherapy and the war on cancerNature Reviews Cancer, 2005
- Attenuated Salmonella typhimurium Containing Interleukin-2 Decreases MC-38 Hepatic Metastases: A Novel Anti-tumor AgentCancer Biotherapy and Radiopharmaceuticals, 1996